KBC Group’s NewAmsterdam Pharma NAMS Stock Holding History

KBC Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$84K	Buy	2,483 +1,312	+112%	+$43.2K	﹤0.01%	1505
2026 Q1	$37K	Buy	+1,171	New	+$38.1K	﹤0.01%	1747

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

KBC Group's NAMS Position: Q2 2026 in Review

KBC Group increased its NewAmsterdam Pharma (NAMS) stake by 112% in Q2 2026, buying an estimated $43.2K and bringing the position to 2,483 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

KBC Group first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

KBC Group held 2,483 shares of NewAmsterdam Pharma worth $84K as of Q2 2026.
KBC Group bought 1,312 NewAmsterdam Pharma shares in Q2 2026, an estimated $43.2K.
NewAmsterdam Pharma made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1505 holding.
KBC Group first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.